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Chemotherapy regimens used to treat non-Hodgkin
lymphoma (NHL), such as cyclophosphamide, dox-
orubicin, vincristine, and prednisone (CHOP), with
or without rituximab, are associated with a high
( 20%) risk of febrile neutropenia (FN) [1]. Older
age is an additional risk factor for FN [1,2], and
existing comorbidities increase FN-associated mor-
tality [3].
Neutropenic complications are potentially life-
threatening [4] and represent the most frequent
dose-limiting toxicity of myelosuppressive che-
motherapy [1,5], often resulting in treatment delays
and dose reductions [6]. For low relative dose
intensity (RDI), which is especially common among
older patients with NHL [7], an association with
poorer outcomes has been reported [8], emphasizing
that when a curative regimen has been selected and
planned, there should be as little deviation from the
planned dose intensity as possible. Colony-stimulat-
ing factors (CSFs) have been shown to reduce the
incidence and severity of neutropenic events across a
broad range of malignancies and regimens, support-
ing the delivery of full chemotherapy dose intensity
[1,5,9].
The Impact of Neutropenia in Chemotherapy –
European Study Group (INC-EU) prospective,
observational study previously reported the incidence
and risk of chemotherapy-induced neutropenia
(CIN), FN, and dose modiﬁcations in patients with
breast cancer and lymphoma [10]. In comparison to
patients with breast cancer, those with lymphoma
experienced higher incidences of FN and grade IV
neutropenia. Here we present results from a sub-
analysis of patients with NHL, assessing the impact
of age on the frequency of neutropenic events,
chemotherapy delivery, and CSF use.
The INC-EU prospective, observational study
enrolled 749 patients with breast cancer or lympho-
ma initiating a new course of chemotherapy during
2004–2005, recruited from 66 clinical centers in
Belgium, France, Germany, Spain, and the UK [10].
Inclusion and exclusion criteria for this study have
been previously reported in detail [10]. For this
subgroup analysis, patients with NHL (n¼240) were
divided into three age groups:  60 years (n¼84),
61–70 years (n¼77), and 470 years (n¼79). The
primary outcome measure was incidence of CIN;
secondary outcome measures were incidence of FN,
patterns of chemotherapy delivery (dose delays/
reductions, RDI, and non-completion), and use of
CSFs and risk of death (in the presence and absence
of FN). Grade IV neutropenia was deﬁned as an
absolute neutrophil count (ANC) 50.5610
9/L and
FN as grade IV neutropenia and temperature  388C.
CSF use was deﬁned as primary prophylaxis (CSF
use in the ﬁrst cycle before a documented grade
III–IV CIN occurred or denoted as primary prophy-
laxis by study site) or reactive use (secondary CSF
prophylaxis in cycles other than the ﬁrst, or CSF
used as treatment). Baseline, treatment, and out-
come parameters were summarized by age group and
compared. The temporal relationship of dose delays
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Causes of death and treatment discontinuation in the
highest age group were evaluated on a patient-by-
patient basis.
Baseline characteristics were comparable between
groups, except for parameters known to vary with age
(Table I). The incidence of cardiovascular and
cardiac comorbidities, lactate dehydrogenase 4500
IU/L, and glucose 4160 mg/dL (8.8 mmol/L)
increased with age, and the glomerular ﬁltration
rate decreased with age. In addition, the proportion
of female patients increased with age.
The majority of patients received CHOP, either
on a 3-weekly (74%) or 2-weekly (17%) schedule.
The proportion of patients with 2-weekly CHOP
increased with age (8%, 17%, and 27% of patients
aged  60, 61–70, and 470 years, respectively). For
most patients, six cycles of chemotherapy were
planned across all age groups. In the  60, 61–70,
and 470 year-old groups, 83%, 83%, and 79% of
patients, respectively, received rituximab.
Grade IV CIN and FN occurred frequently in all
age groups. Overall, 54% of patients experienced
grade IV CIN; there was a trend toward an increased
incidence with age [Figure 1(A)]. Twenty-two
percent of patients developed FN in any cycle; the
incidence did not increase with age [Figure 1(B)].
The relative risk (RR) of death for patients who
experienced FNinany cycle,versus thosewithoutFN,
was 1.7 for the younger age groups combined (95%
conﬁdence interval [CI] 0.2–18.6; p¼0.535). For
patients 470 years, the RR was 10.9 (95% CI 2.4–
49.4; p¼0.001), suggesting that although the inci-
dence of FN did not increase with age, patients in this
age group were at increased risk of death from FN.
Overall, 28% of patients received primary CSF
prophylaxis and 29% of patients required other CSF
use. Use of daily CSF (ﬁlgrastim) was highest in
patients aged 61–70 years; pegﬁlgrastim was used
most frequently in patients 470 years. The propor-
tion of patients receiving primary CSF prophylaxis
was comparable across all age groups (24%, 29%,
and 30% of patients aged  60, 61–70, and 470
years, respectively). Reactive CSF use was seen
frequently and to a similar extent in each age group
(32%, 25%, and 29% of patients aged  60, 61–70,
and 470 years, respectively).
Patients in the oldest age group were less likely to
complete their planned treatment: 27% of patients
470 years did not complete their planned che-
motherapy, as compared to 19% and 14% of patients
aged  60 and 61–70 years, respectively. Of the non-
completers 470 years, 48% discontinued due to
adverse events, 38% died, and 14% withdrew
consent or were discontinued due to non-compli-
ance. In this age group, 90% of adverse events
leading to discontinuation and 88% of deaths
involved CIN, FN, or infection.
The occurrence of dose delays, dose reductions,
and RDI  85% is shown in Figure 1(C). The
proportion of patients with dose delays  4 days
increased with age. Figure 1(D) shows the propor-
tion of dose delays that occurred in the absence of
neutropenic events, after grade IV CIN, or after FN.
With increasing age, a greater proportion of patients
experienced dose delays in the absence of neutrope-
nia, and in the presence of grade IV CIN without
FN. The proportion of patients with dose reductions
 10% was comparable across age groups. RDI
 85% occurred in 30% of patients overall, and was
most frequent in patients 470 years (almost 40% of
this group) [Figure 1(C)].
The high incidence of RDI  85% in patients 470
years appears to have been driven by an increased
number of dose delays in these patients, which may
have protected against FN, possibly explaining why
FN rates in this group were not higher than the
overall average. This potential protective effect of
dose delays was not attributable to pre-planned
decreases in RDI, which would have been recorded
separately, as per study protocol.
Although rates of FN were similar across age
groups, myelosuppression impacted most strongly on
Table I. Patient and disease characteristics.
Characteristic
 60 years
(n¼84)
61–70 years
(n¼77)
470 years
(n¼79)
Age in years:
mean+SD
49.0+9.5 65.9+3.1 75.9+4.4
Female gender: pts (%) 28 (33.3) 33 (42.9) 44 (55.7)
Body surface area*:
mean+SD
1.89+0.19 1.84+0.16 1.78+0.18
IPI index: pts
{ (%)
Low (0–1) 42 (51.2) 16 (20.8) 17 (21.8)
Intermediate (2–3) 35 (42.7) 49 (63.6) 48 (61.5)
High ( 4) 5 (6.1) 12 (15.6) 13 (16.7)
Glomerular ﬁltration
rate in mL/min
{:
mean+SD
105+31 79+25 63+18
ANC 51.5610
9/L:
pts
{ (%)
4 (4.9) 4 (5.4) 2 (2.6)
Cardiovascular
comorbidity: pts (%)
14 (16.7) 18 (23.4) 33 (41.8)
Cardiac comorbidity:
pts (%)
7 (8.3) 10 (13.0) 15 (19.0)
Liver comorbidity:
pts (%)
1 (1.2) 2 (2.6) 2 (2.5)
Renal comorbidity:
pts (%)
3 (3.6) 7 (9.1) 6 (7.6)
*Calculated using the Mosteller formula.
{n5expected due to missing values.
{Estimated using the Cockroft–Gault formula.
SD, standard deviation; pts, patients; ANC, absolute neutrophil
count.
1134 Letter to the Editoroutcomes in patients 470 years, who were at higher
risk of FN-related mortality and more likely to
discontinue treatment due to CIN, FN, and infec-
tious complications. Although most elderly patients
with cancer can tolerate standard chemotherapy
regimens [5], our data suggest that patients 470
years are at higher risk of a worse outcome following
a neutropenic event. Appropriate supportive care and
close clinical monitoring are therefore of particular
importance for this population. Results of a recent
integrated analysis suggested that elderly patients
with breast cancer ( 65 years) beneﬁted from
primary prophylaxis with pegﬁlgrastim: the incidence
of FN, dose reductions, and FN-related hospitaliza-
tions was reduced in these patients, in comparison
to those receiving current practice neutropenia
management [11].
Despite the fact that the European Organisation
for Research and Treatment of Cancer (EORTC)
guidelines for the elderly recommend that prophy-
lactic CSF is given to all patients 465 years receiving
myelotoxic chemotherapy [12], there was no in-
creased use of CSF in patients 470 years as
compared to younger patients, either as primary
prophylaxis or reactive use. A considerable propor-
tion of patients required CSF as secondary prophy-
laxis or treatment. This, together with the overall
high FN rate and low RDI, may suggest a false
economy: where primary CSF prophylaxis is not
given, a substantial proportion of patients require
reactive initiation of CSF during their treatment
course.
In summary, CIN and FN were considerable in
patients with NHL across all age groups. Although
FN rates were similar across all age groups,
myelosuppression had the greatest impact on patients
470 years, suggesting that CSF prophylaxis may be
particularly relevant for this population.
Potential conﬂict of interest: Disclosure forms
provided by the authors are available with the full text
of this article at www.informahealthcare.com/lal.
Medcept ltd, Switzerland, provided medical writing
support on behalf of Amgen (Europe) GmbH.
Figure 1. Incidence of CIN and dose modiﬁcations with age. Incidence of (A) grade IV CIN (ANC5500/mm
3 or, if ANC unavailable,
white blood cell count51000/mm
3) and (B) FN (grade IV CIN plus fever [ 388C]) in cycle 1 and in any cycle. Error bars represent 95%
CIs. (C) Proportion of patients experiencing dose delays 4 days, dose reductions 10%, and RDI 85%. Non-administered cycles were
taken into account to calculate dose reductions and RDI, except in the case of patient death. Error bars represent 95% CIs. (D) Proportion of
patients experiencing dose delays 4 days after FN, after grade IV CIN but in the absence of FN, and in the absence of a neutropenic event.
CIN, chemotherapy-induced neutropenia; ANC, absolute neutrophil count; FN, febrile neutropenia; CI, conﬁdence interval; RDI, relative
dose intensity.
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